Radiopharm Theranostics Ltd (RADX) Total Liabilities (2023 - 2026)

Radiopharm Theranostics (RADX) has reported Total Liabilities for 4 consecutive years, with $268205.8 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Total Liabilities fell 3.97% year-over-year to $268205.8 in Q2 2026; TTM through Jun 2026 was $268205.8, a 3.97% decrease from a year earlier, with the FY2026 full-year figure at $256789.6, down 99.41% from the prior year.
• Total Liabilities was $268205.8 for Q2 2026 at Radiopharm Theranostics, down from $279292.7 in the prior quarter.
• Over five years, Total Liabilities peaked at $40.4 million in Q4 2024 and troughed at -$45.6 million in Q2 2023.
• A 4-year average of -$857787.2 and a median of $279292.7 in 2025 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities surged 100.65% in 2024 and dropped 5.15% in 2025, its largest moves.
• Over 4 years, Total Liabilities stood at -$45.6 million in 2023, then surged by 188.74% to $40.4 million in 2024, then plunged by 99.31% to $279292.7 in 2025, then decreased by 3.97% to $268205.8 in 2026.
• The last three Total Liabilities figures came in at $268205.8 (Q2 2026), $279292.7 (Q2 2025), and $40.4 million (Q4 2024), per Business Quant data.